Cargando…

Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma

SIMPLE SUMMARY: Melanoma is a cancer of cells that produce melanin pigment, and it can develop in dogs as well as in humans. Canine melanoma has a high risk of metastasis and is resistant to systemic chemotherapy. Therefore, alternative effective systemic treatment is urgently needed. Abnormal expre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koo, Karen, Wuenschmann, Arno, Rendahl, Aaron, Song, Kyu Young, Forster, Colleen, Wolf-Ringwall, Amber, Borgatti, Antonella, Giubellino, Alessio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144085/ https://www.ncbi.nlm.nih.gov/pubmed/37104404 http://dx.doi.org/10.3390/vetsci10040249

Ejemplares similares

Computed tomography radiomic features hold prognostic utility for canine lung tumors: An analytical study
por: Able, Hannah, et al.
Publicado: (2021)

MET Receptor Tyrosine Kinase Inhibition Reduces Interferon-Gamma (IFN-γ)-Stimulated PD-L1 Expression through the STAT3 Pathway in Melanoma Cells
por: Song, Kyu Young, et al.
Publicado: (2023)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
por: Demkova, Lucia, et al.
Publicado: (2018)

Correlation of MET and PD-L1 Expression in Malignant Melanoma
por: Song, Kyu Young, et al.
Publicado: (2020)

MACC1 and MET as markers associated with progression and metastasis in cutaneous melanoma
por: Zhou, Yan, et al.
Publicado: (2023)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Origin and evolution of plexins, semaphorins, and Met receptor tyrosine kinases
por: Junqueira Alves, Chrystian, et al.
Publicado: (2019)

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

Multimodal Treatment of a Canine Lingual Melanoma Using a Combination of Immunotherapy and a Tyrosine Kinase Inhibitors
por: Berry, Alexander, et al.
Publicado: (2022)

Activating MET Kinase Rearrangements in Melanoma and Spitz Tumors
por: Yeh, Iwei, et al.
Publicado: (2015)

Canine pulmonary adenocarcinoma tyrosine kinase receptor expression and phosphorylation
por: Mariotti, Evan T, et al.
Publicado: (2014)

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
por: Zhang, Yazhuo, et al.
Publicado: (2018)

Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase
por: Fernandes, Marie, et al.
Publicado: (2019)

Tyrosine kinase inhibitors as an alternative treatment in canine mast cell tumor
por: Coelho, Yasmin Nascimento Bernardes, et al.
Publicado: (2023)

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
por: Welsh, James W, et al.
Publicado: (2009)

A new synaptic player leading to autism risk: Met receptor tyrosine kinase
por: Judson, Matthew C., et al.
Publicado: (2011)

Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
por: Zhao, Yuanyuan, et al.
Publicado: (2015)

c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2015)

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma
por: Catenacci, Daniel V. T., et al.
Publicado: (2016)

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase
por: Yao, Hang-Ping, et al.
Publicado: (2021)

The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis
por: Passelli, Katiuska, et al.
Publicado: (2022)

Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor
por: Halsey, Charles HC, et al.
Publicado: (2014)

Variability in Recommendations for Cervical Lymph Node Pathology for Staging of Canine Oral Neoplasia: A Survey Study
por: Congiusta, Michael, et al.
Publicado: (2020)

The Met receptor tyrosine kinase prevents zebrafish primary motoneurons from expressing an incorrect neurotransmitter
por: Tallafuss, Alexandra, et al.
Publicado: (2008)

CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
por: Tan, Yi-Hung Carol, et al.
Publicado: (2010)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors
por: Mekki, Meriem Sarah, et al.
Publicado: (2018)

Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering
por: Li, Wenjing, et al.
Publicado: (2019)

Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas
por: Lüttich, Lina, et al.
Publicado: (2021)

MET Receptor Tyrosine Kinase Regulates Lifespan Ultrasonic Vocalization and Vagal Motor Neuron Development
por: Kamitakahara, Anna K., et al.
Publicado: (2021)

An mTOR feedback loop mediates the ‘flare’ (‘rebound’) response to MET tyrosine kinase inhibition
por: Altintas, D. M., et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Correction: CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
por: Tan, Yi-Hung Carol, et al.
Publicado: (2011)

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
por: Agwa, Eberechi S, et al.
Publicado: (2014)

Age dependent forebrain structural changes in mice deficient in the autism associated gene Met tyrosine kinase()
por: Smith, Jacob M., et al.
Publicado: (2012)

Complete or partial reduction of the Met receptor tyrosine kinase in distinct circuits differentially impacts mouse behavior
por: Thompson, Barbara L., et al.
Publicado: (2015)

The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response — Biological and Clinical Aspects
por: Medová, Michaela, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cp7j6tvefvbeeuqappi6690ohl